184 results on '"Lynn RC"'
Search Results
2. Hepatocellular carcinoma-specific epigenetic checkpoints bidirectionally regulate the antitumor immunity of CD4 + T cells
3. Developing CAR T-Cell Therapies for Pediatric Solid Tumors
4. Rational combinatorial targeting by adapter CAR-T-cells (AdCAR-T) prevents antigen escape in acute myeloid leukemia
5. The long-term effectiveness and mechanism of oncolytic virotherapy combined with anti-PD-L1 antibody in colorectal cancer patient
6. LILRB1-HLA-G axis defines a checkpoint driving natural killer cell exhaustion in tuberculosis
7. Improved CAR-T cell activity associated with increased mitochondrial function primed by galactose
8. Immunosuppressive regulatory cells in cancer immunotherapy: restrain or modulate?
9. The expression of PD-L1 on tumor-derived exosomes enhances infiltration and anti-tumor activity of αCD3 × αPD-L1 bispecific antibody-armed T cells
10. Advances in manufacturing chimeric antigen receptor immune cell therapies
11. Trogocytosis in CAR immune cell therapy: a key mechanism of tumor immune escape
12. Phenotypic and spatial heterogeneity of CD8+ tumour infiltrating lymphocytes
13. Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy
14. Multi-omics analysis reveals a feedback loop amplifying immune responses in acute graft-versus-host disease due to imbalanced gut microbiota and bile acid metabolism
15. Beyond CAR-T: The rise of CAR-NK cell therapy in asthma immunotherapy
16. An update to experimental and clinical aspects of tumor-associated macrophages in cancer development: hopes and pitfalls
17. Deciphering the tumor immune microenvironment from a multidimensional omics perspective: insight into next-generation CAR-T cell immunotherapy and beyond
18. CDK4/6 inhibition enhances T-cell immunotherapy on hepatocellular carcinoma cells by rejuvenating immunogenicity
19. Integrated analysis of tumor-associated macrophages and M2 macrophages in CRC: unraveling molecular heterogeneity and developing a novel risk signature
20. Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer
21. The potential and promise for clinical application of adoptive T cell therapy in cancer
22. Tumor immune dysfunction and exclusion subtypes in bladder cancer and pan-cancer: a novel molecular subtyping strategy and immunotherapeutic prediction model
23. Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors
24. Functional CRISPR screens in T cells reveal new opportunities for cancer immunotherapies
25. Identification of a disulfidptosis-related lncRNA signature for the prognostic and immune landscape prediction in head and neck squamous cell carcinoma
26. The construction of modular universal chimeric antigen receptor T (MU-CAR-T) cells by covalent linkage of allogeneic T cells and various antibody fragments
27. Gene editing technology to improve antitumor T-cell functions in adoptive immunotherapy
28. Comprehensive analysis of T cell exhaustion related signature for predicting prognosis and immunotherapy response in HNSCC
29. Challenges and strategies associated with CAR-T cell therapy in blood malignancies
30. Macrophage heterogeneity and its interactions with stromal cells in tumour microenvironment
31. Emerging mechanisms of the unfolded protein response in therapeutic resistance: from chemotherapy to Immunotherapy
32. BATF and BATF3 deficiency alters CD8+ effector/exhausted T cells balance in skin transplantation
33. Myeloid leukemia-derived galectin-1 downregulates CAR expression to hinder cytotoxicity of CAR T cells
34. Synthetic biology approaches for improving the specificity and efficacy of cancer immunotherapy
35. Transcription factors in chimeric antigen receptor T-cell development
36. Chemical genetic control of cytokine signaling in CAR-T cells using lenalidomide-controlled membrane-bound degradable IL-7
37. Harnessing the tumor microenvironment to boost adoptive T cell therapy with engineered lymphocytes for solid tumors
38. Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy
39. GPC3-IL7-CCL19-CAR-T primes immune microenvironment reconstitution for hepatocellular carcinoma therapy
40. CD19-targeted chimeric antigen receptor T-cell therapy in patients with concurrent B-cell Non-Hodgkin lymphoma and rheumatic autoimmune diseases: a propensity score matching study
41. Developing Strategies to Improve the Efficacy of CAR-T Therapy for Acute Myeloid Leukemia
42. Culture expansion of CAR T cells results in aberrant DNA methylation that is associated with adverse clinical outcome
43. Investigating potential immune mechanisms of trilaciclib administered prior to chemotherapy in patients with metastatic triple-negative breast cancer
44. Multivalent adaptor proteins specifically target NK cells carrying a universal chimeric antigen receptor to ErbB2 (HER2)-expressing cancers
45. Recovering ancient parasites from Andean herbivores: test of the Mini-FLOTAC technique in archaeological samples
46. Oncolytic viruses improve cancer immunotherapy by reprogramming solid tumor microenvironment
47. The duality of CXCR3 in glioblastoma: unveiling autocrine and paracrine mechanisms for novel therapeutic approaches
48. Targeting the epigenome to reinvigorate T cells for cancer immunotherapy
49. Exploiting innate immunity for cancer immunotherapy
50. Challenges and new technologies in adoptive cell therapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.